Vanguard Group Inc. holds a significant stake of 118,983,644 shares, valued at $13.21 billion, in Gilead Sciences, despite a slight reduction of 0.3% in Q3. Gilead recently reported better-than-expected Q4 results, raising its FY2026 guidance and leading to multiple analyst price target increases, with a consensus of “Moderate Buy” at $152.50. The company also increased its quarterly dividend to $0.82, reflecting positive sentiment and strong financial performance.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Vanguard Group Inc. Has $13.21 Billion Stake in Gilead Sciences, Inc. $GILD
Vanguard Group Inc. holds a significant stake of 118,983,644 shares, valued at $13.21 billion, in Gilead Sciences, despite a slight reduction of 0.3% in Q3. Gilead recently reported better-than-expected Q4 results, raising its FY2026 guidance and leading to multiple analyst price target increases, with a consensus of “Moderate Buy” at $152.50. The company also increased its quarterly dividend to $0.82, reflecting positive sentiment and strong financial performance.